Thalidomide for the treatment of angiodysplasia‐related recurrent gastrointestinal hemorrhage: Is low dose a safe and viable option?

Abstract

Abstract Thalidomide is often used for the management of refractory gastrointestinal angiodysplasia (GIAD). The tolerance, toxic profile, and compliance of thalidomide are dose‐dependent. The low‐dose thalidomide (50 mg) is safe and a viable option for bleeding related to GIAD.

Keywords

• angiodyslasia and pharmacological management
• angiodysplasia and thalidomide
• low‐dose thalidomide and GI bleed
• thalidomide and small bowel AVM